Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Parkinson’s drug found effective

14.01.2003


A study conducted on 404 patients at several U.S. sites has determined that a new drug called Rasagiline effectively treats early-stage Parkinson’s disease. The study was reported in the December Archives of Neurology.



"These findings are especially important since hopes for treating Parkinson’s with fetal cells were recently dashed," said Technion-Israel Institute of Technology Professor Moussa Youdim, who developed Rasagiline with Prof. John Finberg of the Department of Pharmacology at the Technion.

The study was conducted as part of the clinical trials for FDA approval. Rasagiline is now in the last stage of the approval process with a decision expected later this year. Teva Pharmaceuticals will then market the new drug.


Research participants were randomized in the double-blind, placebo-controlled study. Participants were given 1 or 2 milligrams a day for one week, followed by a 25-week maintenance period.

The treatment’s effectiveness was measured by Unified Parkinson’s Disease Rating Scale (UPDR) and compared with the control group that received a placebo. The group that received 1 milligram showed an improvement of 4.2 UPDR units on average. Those who received 2 milligrams showed an improvement of 3.56 UPDR units.

The report called for further study to evaluate Rasagiline’s long-term effects on the progression of the disease. This is now in progress.

Prof. Youdim heads the Eve Topf Neuro-Degenerative Disease Research and Teaching Center at the Faculty of Medicine at the Technion, where he develops a variety of drugs for neurodegenerative diseases. As early as 1975, Prof. Youdim and colleagues introduced I-Deprenyl (Selegiline), a drug that has been shown to slow the progress of Parkinson’s disease.

Contact: Martha Molnar
e-mail: martha@ats.org

Martha Molnar | EurekAlert!

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Midwife and signpost for photons

11.12.2017 | Physics and Astronomy

How do megacities impact coastal seas? Searching for evidence in Chinese marginal seas

11.12.2017 | Earth Sciences

PhoxTroT: Optical Interconnect Technologies Revolutionized Data Centers and HPC Systems

11.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>